Transgene SA (0OCQ.L)
| Previous close | 2.0332 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 130.361M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of December 31, 2022
STRASBOURG, France, January 17, 2023--Regulatory News: Under the liquidity contract entrusted by Transgene (Paris:TNG) to Natixis Oddo BHF SCA, as of December 31, 2022, the following resources were managed through the liquidity account:
- Business Wire
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
STRASBOURG, France, January 06, 2023--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase I clinical trial of TG6050, a novel oncolytic virus (OV) that will be administered intravenously in patients with
- Business Wire
Transgene Announces Financial Calendar for 2023
STRASBOURG, France, January 04, 2023--Regulatory News: TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2023:
